Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer.

Ali AI, Oliver AJ, Samiei T, Chan JD, Kershaw MH, Slaney CY.

Front Oncol. 2019 Feb 12;9:56. doi: 10.3389/fonc.2019.00056. eCollection 2019. Review.

2.

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells.

Beavis PA, Henderson MA, Giuffrida L, Davenport AJ, Petley EV, House IG, Lai J, Sek K, Milenkovski N, John LB, Mardiana S, Slaney CY, Trapani JA, Loi S, Kershaw MH, Haynes NM, Darcy PK.

Cancer Immunol Res. 2018 Sep;6(9):1069-1081. doi: 10.1158/2326-6066.CIR-18-0291. Epub 2018 Jul 17.

PMID:
30018045
3.

CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment.

Slaney CY, Wang P, Darcy PK, Kershaw MH.

Cancer Discov. 2018 Aug;8(8):924-934. doi: 10.1158/2159-8290.CD-18-0297. Epub 2018 Jul 16. Review.

PMID:
30012854
4.

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.

Oliver AJ, Lau PKH, Unsworth AS, Loi S, Darcy PK, Kershaw MH, Slaney CY.

Front Immunol. 2018 Jan 31;9:70. doi: 10.3389/fimmu.2018.00070. eCollection 2018. Review.

5.

An ultrastructural investigation of tumors undergoing regression mediated by immunotherapy.

Westwood JA, Ellis S, Danne J, Johnson C, Oorschot V, Ramm G, Tscharke DC, Davenport AJ, Whisstock JC, Darcy PK, Kershaw MH, Slaney CY.

Oncotarget. 2017 Dec 14;8(70):115215-115229. doi: 10.18632/oncotarget.23215. eCollection 2017 Dec 29.

6.

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK.

J Clin Invest. 2017 Mar 1;127(3):929-941. doi: 10.1172/JCI89455. Epub 2017 Feb 6.

7.

A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.

Mardiana S, John LB, Henderson MA, Slaney CY, von Scheidt B, Giuffrida L, Davenport AJ, Trapani JA, Neeson PJ, Loi S, Haynes NM, Kershaw MH, Beavis PA, Darcy PK.

Cancer Res. 2017 Mar 15;77(6):1296-1309. doi: 10.1158/0008-5472.CAN-16-1831. Epub 2017 Jan 12.

8.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

9.

Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.

Beavis PA, Slaney CY, Kershaw MH, Gyorki D, Neeson PJ, Darcy PK.

Semin Immunol. 2016 Feb;28(1):64-72. doi: 10.1016/j.smim.2015.11.003. Epub 2015 Nov 25. Review.

PMID:
26611350
10.

CD73: A potential biomarker for anti-PD-1 therapy.

Beavis PA, Slaney CY, Milenkovski N, Henderson MA, Loi S, Stagg J, Kershaw MH, Darcy PK.

Oncoimmunology. 2015 May 5;4(11):e1046675. eCollection 2015 Nov.

11.

Releasing the Brake on Oncolytic Viral Therapy.

Slaney CY, Darcy PK.

Clin Cancer Res. 2015 Dec 15;21(24):5417-9. doi: 10.1158/1078-0432.CCR-15-1769. Epub 2015 Sep 16.

12.

Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene.

Yong CS, Sharkey J, Duscio B, Venville B, Wei WZ, Jones RF, Slaney CY, Mir Arnau G, Papenfuss AT, Schröder J, Darcy PK, Kershaw MH.

PLoS One. 2015 Sep 3;10(9):e0136817. doi: 10.1371/journal.pone.0136817. eCollection 2015.

13.

Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer.

Rautela J, Baschuk N, Slaney CY, Jayatilleke KM, Xiao K, Bidwell BN, Lucas EC, Hawkins ED, Lock P, Wong CS, Chen W, Anderson RL, Hertzog PJ, Andrews DM, Möller A, Parker BS.

Cancer Immunol Res. 2015 Nov;3(11):1207-17. doi: 10.1158/2326-6066.CIR-15-0065. Epub 2015 Jul 21.

14.

Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.

Beavis PA, Slaney CY, Kershaw MH, Neeson PJ, Darcy PK.

Immunotherapy. 2015;7(5):499-512. doi: 10.2217/imt.15.16. Review.

PMID:
26065476
15.

Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.

Duong CP, Yong CS, Kershaw MH, Slaney CY, Darcy PK.

Mol Immunol. 2015 Oct;67(2 Pt A):46-57. doi: 10.1016/j.molimm.2014.12.009. Epub 2015 Jan 13. Review.

PMID:
25595028
16.

Clinical application of genetically modified T cells in cancer therapy.

Kershaw MH, Westwood JA, Slaney CY, Darcy PK.

Clin Transl Immunology. 2014 May 16;3(5):e16. doi: 10.1038/cti.2014.7. eCollection 2014 May. Review.

17.

Trafficking of T cells into tumors.

Slaney CY, Kershaw MH, Darcy PK.

Cancer Res. 2014 Dec 15;74(24):7168-74. doi: 10.1158/0008-5472.CAN-14-2458. Epub 2014 Dec 4. Review.

18.

BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity.

Cao Y, Slaney CY, Bidwell BN, Parker BS, Johnstone CN, Rautela J, Eckhardt BL, Anderson RL.

Cancer Res. 2014 Sep 15;74(18):5091-102. doi: 10.1158/0008-5472.CAN-13-3171.

19.

The emerging role of immunosurveillance in dictating metastatic spread in breast cancer.

Slaney CY, Rautela J, Parker BS.

Cancer Res. 2013 Oct 1;73(19):5852-7. doi: 10.1158/0008-5472.CAN-13-1642. Epub 2013 Sep 23. Review.

20.

The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone.

Slaney CY, Möller A, Hertzog PJ, Parker BS.

Oncoimmunology. 2013 Jan 1;2(1):e22339.

21.

A modified superantigen rescues Ly6G- CD11b+ blood monocyte suppressor function and suppresses antigen-specific inflammation in EAE.

Slaney CY, Toker A, Fraser JD, Harper JL, Bäckström BT.

Autoimmunity. 2013 Jun;46(4):269-78. doi: 10.3109/08916934.2013.767893.

PMID:
23374140
22.

Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape.

Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, Andrews D, Mikeska T, Mangan NE, Samarajiwa SA, de Weerd NA, Gould J, Argani P, Möller A, Smyth MJ, Anderson RL, Hertzog PJ, Parker BS.

Nat Med. 2012 Aug;18(8):1224-31. doi: 10.1038/nm.2830. Epub 2012 Jul 22.

PMID:
22820642
23.

Glatiramer acetate treatment directly targets CD11b(+)Ly6G(-) monocytes and enhances the suppression of autoreactive T cells in experimental autoimmune encephalomyelitis.

Toker A, Slaney CY, Bäckström BT, Harper JL.

Scand J Immunol. 2011 Sep;74(3):235-243. doi: 10.1111/j.1365-3083.2011.02575.x.

24.

Naïve blood monocytes suppress T-cell function. A possible mechanism for protection from autoimmunity.

Slaney CY, Toker A, La Flamme A, Bäckström BT, Harper JL.

Immunol Cell Biol. 2011 Jan;89(1):7-13. doi: 10.1038/icb.2010.110. Epub 2010 Nov 9.

PMID:
21060323

Supplemental Content

Loading ...
Support Center